| Name | Title | Contact Details |
|---|
Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.
Jnana was founded by leading academic scientists, drug developers and investors to develop medicines that transform the lives of patients by targeting the cell`s metabolic gates.
Octave is developing a comprehensive, first-in-class Care Management Platform.
MedWorxs is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clovis Oncology is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.